The introduction of human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab, pertuzumab, and lapatinib, has contributed to advancements in the outcomes of advanced gastric cancer patients [6]. Here, ERBB2 is linked to gastric cancer.